title: Combined effect of microRNA, nutraceuticals and drug on pancreatic cancer cell lines.
abstract: OBJECTIVE
  We proposed to investigate the combination effect of microRNA, nutraceuticals and drug (MND), in two pancreatic cancer cell lines to assess the therapeutic potential.
  
  
  METHODS
  MIA PaCa-2 and PANC-1 cells transfected with miR-101 or miR-24-2 were treated with Betulinic acid or Thymoquinone and gemcitabine independently and in combination and assessed for the extent of synergism in both experimental and control conditions, considering significance at the p value of <0.05.
  
  
  RESULTS
  miR-101 or miR-24-2 over-expressing cells when treated with lower than IC50 doses of the dietary compounds and drug showed a reduced (37-50%) viability in two cell lines with differential synergistic effect and the outcome for Pro-caspase3, Poly (ADP-ribose) polymerase (PARP) cleavage and PKM2 expression.
  
  
  CONCLUSIONS
  Two independent microRNA backgrounds showed promise in therapeutic intervention of gemcitabine sensitive, MIA PaCa-2 and resistant, PANC-1 pancreatic cancer cells, in combination with dietary agents and drug.
authors.affiliation: School of Biotechnology, Shri Mata Vaishno Devi University, Katra, J&K, India.
authors.forename: Archana
authors.initials: A
authors.lastname: Pandita
authors.affiliation: School of Biotechnology, Shri Mata Vaishno Devi University, Katra, J&K, India.
authors.forename: Siddharth
authors.initials: S
authors.lastname: Manvati
authors.affiliation: Indian Institute of Integrative Medicine, CSIR, J&K, India.
authors.forename: Shashank K
authors.initials: SK
authors.lastname: Singh
authors.affiliation: School of Biotechnology, Shri Mata Vaishno Devi University, Katra, J&K, India. Electronic address: samantha.vaishnavi@smvdu.ac.in.
authors.forename: Samantha
authors.initials: S
authors.lastname: Vaishnavi
authors.affiliation: School of Life Sciences, Jawaharlal Nehru University, New Delhi, India. Electronic address: bamezai@hotmail.com.
authors.forename: Rameshwar N K
authors.initials: RN
authors.lastname: Bamezai
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D016227:Benzoquinones / Q000494:pharmacology*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000494:pharmacology; D019587:Dietary Supplements / Q000032:analysis; D004357:Drug Synergism; D006801:Humans; D035683:MicroRNAs / Q000235:genetics*; D010179:Pancreas / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D053978:Pentacyclic Triterpenes; D014162:Transfection; D014315:Triterpenes / Q000494:pharmacology*; D000094062:Betulinic Acid; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D016227:Benzoquinones; C534072:MIRN101 microRNA, human; C543845:MIRN24 microRNA, human; D035683:MicroRNAs; D053978:Pentacyclic Triterpenes; D014315:Triterpenes; D003841:Deoxycytidine; C003466:thymoquinone; D000094062:Betulinic Acid; D000093542:Gemcitabine
keywords: GCB; MIA PaCa-2; PANC-1; Pancreatic cancer; Synergism; microRNA